Global pharmaceutical development and access: Critical issues of ethics and equity

MEDICC Review

Volumn 13, Issue 3, 2011, Pages 16-22

  Dávila, Agustín Lage ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Access to health care; Biological products; Biotechnology; Brazil; Clinical trials; Cuba; Drug costs; Economics; Intellectual property; Patents; Pharmaceutical; Pharmaceutical preparations; World health

Indexed keywords

BRAZIL; CUBA; DRUG COST; DRUG UTILIZATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; MEDICAL ETHICS; PATENT; POLITICS; REVIEW; SOCIOECONOMICS; TREND STUDY; WORLD HEALTH ORGANIZATION;

EID: 79960680386     PISSN: 15557960     EISSN: 15273172     Source Type: Journal    
DOI: 10.1590/S1555-79602011000300005     Document Type: Review

References (25)

1. Perehudoff SK. Health, Essential Medications. Human Rights & National Constitutions. Bull World Health Organ [Internet]. 2008 Jul [cited 2011 Mar 18]. Available from: http://www.who.int/medicines/areas/human-rights/Perehudoff- report-constitutions-2008.pdf
2. Perehudoff SK, Laing RO, Hogerzeil HV. Access to essential medications in national constitutions. Bull World Health Organ. 2010 Nov 1;88(11):800.
3. WHO Medications Strategy. Countries at the core 2004-2007. Geneva: World Health Organization; 2004. 12 p.
4. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability. An international comparison of chronic disease medications [Internet]. Cairo: World Health Organization; 2005 Dec [cited 2011 Mar 18]. 69 p. Available from: http://www.haiweb.org/medicineprices/08092008/EDB068fi nal.pdf
5. WHO. Measuring medicine prices, availability, affordability and price components. 2nd ed. Geneva: World Health Organization; 2008.
6. Jacobzone S. IDEAS [Internet]. Connecticut: University of Connecticut. 2000 Apr. Record No. 40, Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals; [cited 2011 Mar 18]; [about 2 screens]. Available from: http://ideas.repec.org/p/oec/elsaaa/40-en.html
7. The European Parliament. Strategies for the Improvement of Global Human Health [Internet]. Strasbourg: The European Parliament; 2006 Jun 29 [cited 2011 Mar 18]. 55 p. Available from: http://www.itas.fzk.de/eng/etag/document/2006/ elde06a.pdf
8. Newcomer LN. The Responsibility to Pay for Cancer Treatments: A Health Insurer's View of Value. Oncologist. 2010;15 Suppl 1:32-5.
9. Resnik DB. The Distribution of Biomedical Research Resources and International Justice. Dev World Bioeth. 2004 May;4(1):42-57. (Pubitemid 38578385)
10. WHO. The World Health Report-Health Systems Financing: the Path to Universal Coverage [Internet]. Geneva: World Health Organization; 2010 Nov 22 [cited 2011Mar 18]. Available from: http://www.who.int/whr/2010/whr10-en.pdf
11. Kerry VB, Lee K. TRIPS, the Doha declaration and paragraph 6 decisions: what are the remaining steps for protecting access to medications? Global Health. 2007 May 24;3:3.
12. WHO. Public health. Innovation and Intellectual. Property Rights. Report of the Commission on Intellectual Property Rights. Geneva: World Health Organization; 2006.
13. Hoen E. Report of the Commission on Intellectual Property Rights, Innovation and Public Health: a call to governments. Bull World Health Organ. 2006 May;84(5):421-3.
14. Noehrenberg E. Report of the Commission on Intellectual Property Rights, Innovation and Public Health: an industry perspective. Bull World Health Organ. 2006 May;84(5):419-20.
15. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009 Jan 17;373(9659):240-9.
16. Creese A, Gasman N, Mariko M. The world medications situation. Geneva: World Health Organization; 2004.
17. Fojo T, Grady C. How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8.
18. UNESCO. Science Report 2010 [Internet]. Paris: UNESCO Publishing; 2010 Nov 10 [cited 2011 Mar 18]. 541 p. Available from: http://unesdoc.unesco.org/ images/0018/001899/189958e.pdf
19. Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, et al. The availability and affordability of selected essential medications for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007 Apr;85(4):279-88. (Pubitemid 46556727)
20. Chu R, Pugatch M. Biogenerics or Biosimilars? Discussing the Present, Considering the Future. London: Stockholm Network; 2009 Oct. 31 p.
21. EvaluatePharma® World Preview 2016 - Analysis Highlights. London: Evaluate Pharma; 2010 May. 31 p.
22. Lage A. Connecting immunology research to public health: Cuban biotechnology. Nat Immunol. 2008 Feb;9(2):109-12.
23. Van Puymbroeck RV. Basic Survival Needs and Access to medications-Coming to Grips with TRIPS: Conversion + Calculation. J Law Med Ethics. 2010 Fall;38(3):520-49.
24. Lage A. Transforming Cancer Indicators Begs Bold New Strategies from Biotechnology. MEDICC Rev. 2009 Jul;11(3):8-12.
25. Lage A, Crombet T. Control of Advanced Cancer: The Road to Chronicity. Int J Environ Res Public Health. 2011 Mar;8(3):683-97.